Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.52 |
| ▸ | METAP2 | P50579 | 1/20 | 0.48 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29468958 | 1.00 | KDM4E (0.52) | KDM4EALDH1A1MAPTTSHRHSD17B10 | |
| Alcohol SCHEMBL29246862 | 0.92 | BCAT2 (0.50) | KDM4EALDH1A1MAPTTSHRHSD17B10 | |
| SCHEMBL25541451 | 0.82 | ENPP2 (0.40) | KDM4EALDH1A1MAPTTSHRHSD17B10 | |
| SCHEMBL3787789 | 0.81 | BCAT2 (0.42) | KDM4EALDH1A1MAPTTSHRHSD17B10 | |
| Boric Acid SCHEMBL31026556 | 0.80 | ALDH1A1 (0.61) | KDM4EALDH1A1MAPTTSHRHSD17B10 | |
| SCHEMBL18919333 | 0.79 | BCAT2 (0.37) | KDM4EALDH1A1MAPTTSHRHSD17B10 | |
| SCHEMBL29956608 | 0.79 | PARP1 (0.41) | KDM4EALDH1A1MAPTTSHRHSD17B10 | |
| SCHEMBL519802 | 0.79 | ENPP2 (0.41) | KDM4EALDH1A1MAPTPOLBL3MBTL1 | |
| SCHEMBL29446522 | 0.79 | ALDH1A1 (0.59) | KDM4EALDH1A1MAPTTSHRHSD17B10 | |
| SCHEMBL29469063 | 0.79 | ENPP2 (0.41) | KDM4EALDH1A1MAPTPOLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 318 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119081323-A | Wear-resistant impact-resistant high polymer floor and preparation process thereof | 洁玛新材料股份有限公司 | 2024-12-06 | — | — | CN | claimed |
| CN-118063863-A | Double-functional nano-particle for rapidly detecting sterilizing bacteria and preparation method and application thereof | 江苏省农业科学院 | 2024-05-24 | — | — | CN | claimed |
| EP-2718265-B1 | PROCESS FOR PREPARING [(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO]ALKANOIC ACIDS, ESTERS AND AMIDES | AKEBIA THERAPEUTICS INC (US) | 2015-12-16 | — | — | EP | claimed |
| US-9145366-B2 | Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides | AKEBIA THERAPEUTICS, INC. (US) | 2015-09-29 | — | — | US | claimed |
| EP-2718265-A1 | PROCESS FOR PREPARING [(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO]ALKANOIC ACIDS, ESTERS AND AMIDES | Akebia Therapeutics Inc. (US) | 2014-04-16 | — | — | EP | claimed |
| WO-2012170377-A1 | PROCESS FOR PREPARING [(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO]ALKANOIC ACIDS, ESTERS AND AMIDES | AKEBIA THERAPEUTICS INC. (US) | 2012-12-13 | — | — | WO | claimed |
| US-20120309977-A1 | PROCESS FOR PREPARING [(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO]ALKANOIC ACIDS, ESTERS AND AMIDES | AKEBIA THERAPEUTICS INC. (US) | 2012-12-06 | — | — | US | claimed |
| CN-122028918-A | TRIM7 inhibitors and uses thereof | 沙塔克实验室有限公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-4720044-A1 | AROMATIC AMIDES AND CONJUGATES THEREOF AS BINDERS TO TEAD | Beactica Therapeutics AB (SE) | 2026-04-08 | — | — | EP | disclosed |
| US-12378224-B2 | Heteroaryl compounds and their use as Mer inhibitors | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2025-08-05 | — | — | US | disclosed |
| EP-4069697-B1 | CRF RECEPTOR ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES INC (US) | 2025-07-16 | — | — | EP | disclosed |
| WO-2025042797-A1 | TRIM7 INHIBITORS AND USES THEREOF | SHATTUCK LABS, INC. (US) | 2025-02-27 | — | — | WO | disclosed |
| WO-2025042798-A1 | TRIM7 INHIBITORS AND USES THEREOF | SHATTUCK LABS, INC. (US) | 2025-02-27 | — | — | WO | disclosed |
| US-20060111375-A1 | Compound having tgfß inhibitory activity and medicinal composition containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-05-25 | — | — | US | disclosed |
| EP-1643998-A1 | DUAL NK1/NK3 ANTAGONISTS FOR TREATING SCHIZOPHRENIA | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005058876-A1 | PYRAZINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST INFECTIOUS DISEASES | GPC BIOTECH AG (DE) | 2005-06-30 | — | — | WO | disclosed |
| EP-1548008-A1 | COMPOUND HAVING TGF-BETA INHIBITORY ACTIVITY AND MEDICINAL COMPOSITION CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2005-06-29 | — | — | EP | disclosed |
| US-20050119347-A1 | Microbicidal agents on the basis of biphenyl benzamide derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2005-06-02 | — | — | US | disclosed |
| US-20050090533-A1 | Dual NK1/NK3 receptor antagonists | F. HOFMANN-LA ROCHE AG (CH) | 2005-04-28 | — | — | US | disclosed |
| WO-2005002577-A1 | DUAL NK1/NK3 ANTAGONISTS FOR TREATING SCHIZOPHRENIA | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119347-A1 | Microbicidal agents on the basis of biphenyl benzamide derivatives | DDT, MSR1, CYP1B1 | KDM4E 1352/4885ALDH1A1 169/4885MAPT 4798/4885 |
| US-20060111375-A1 | Compound having tgfß inhibitory activity and medicinal composition containing the same | TGFB1, TGFBR1, TGFBR2 | KDM4E 1176/4885ALDH1A1 1257/4885MAPT 2587/4885 |
| US-20050090533-A1 | Dual NK1/NK3 receptor antagonists | TACR2, TAC3, TACR1 | KDM4E 1504/4885ALDH1A1 1516/4885MAPT 4611/4885 |
| US-12378224-B2 | Heteroaryl compounds and their use as Mer inhibitors | MERTK, RET, ERBB2 | KDM4E 1635/4885ALDH1A1 3864/4885MAPT 1125/4885 |
| US-20120309977-A1 | PROCESS FOR PREPARING [(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO]ALKANOIC ACIDS, ESTERS AND AMIDES | HPD, APEH, ALDH7A1 | KDM4E 664/4885ALDH1A1 36/4885MAPT 4149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.